Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Nov 14, 2016
Arbutus Presents HBV Drug Combination Studies at AASLD

Nov 3, 2016
Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results


View all »Events & Presentations

Nov 11, 2016
2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Sep 29, 2016 at 2:00 PM PT
Arbutus Biopharma HBV Product Pipeline Update